ImmuniMed Inc. is an innovative, clinical-stage, Research & Development Biopharmaceutical Company. ImmuniMed Inc. develops oral antibody therapy using passive vaccination to treat and prevent gastro-enteric infections. Their technology is designed to utilize chicken eggs as bioreactors to manufacture specific polyclonal antibodies – a new class of biopharmaceuticals.
member
The Province of Manitoba was host to the 2019 Tri-National Agricultural Accord annual meeting from November 12 to 14 in Winnipeg, Agriculture and Resource Development Minister Blaine Pedersen announced today.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.